The global biosimulation market size was accounted for USD 3.94 billion in 2024, grew to USD 4.61 billion in 2025 and is predicted to surpass around USD 19.00 billion by 2034, representing a healthy CAGR of 17.04% between 2025 and 2034. The North America biosimulation market size was calculated at USD 1.97 billion in 2024 and is expected to grow at a fastest CAGR of 17.07% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Biosimulation Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Biosimulation Market, by Product Type
8.1.1. Software
8.1.1.1. Market Revenue and Forecast
8.1.2. Services
8.1.2.1. Market Revenue and Forecast
9.1. Biosimulation Market, by Application
9.1.1. Drug Discovery
9.1.1.1. Market Revenue and Forecast
9.1.2. Drug Development
9.1.2.1. Market Revenue and Forecast
9.1.3. Others
9.1.3.1. Market Revenue and Forecast
10.1. Biosimulation Market, by End User Type
10.1.1. Regulatory Authorities
10.1.1.1. Market Revenue and Forecast
10.1.2. Pharmaceutical & Biotechnology Companies
10.1.2.1. Market Revenue and Forecast
10.1.3. Contract Research Organizations (CROs)
10.1.3.1. Market Revenue and Forecast
10.1.4. Academic Research Institutes
10.1.4.1. Market Revenue and Forecast
11.1. Biosimulation Market, by Delivery Model Type
11.1.1. Subscription Models
11.1.1.1. Market Revenue and Forecast
11.1.2. Ownership Models
11.1.2.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Product
12.1.2. Market Revenue and Forecast, by Application
12.1.3. Market Revenue and Forecast, by End User Type
12.1.4. Market Revenue and Forecast, by Delivery Model Type
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Product
12.1.5.2. Market Revenue and Forecast, by Application
12.1.5.3. Market Revenue and Forecast, by End User Type
12.1.5.4. Market Revenue and Forecast, by Delivery Model Type
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Product
12.1.6.2. Market Revenue and Forecast, by Application
12.1.6.3. Market Revenue and Forecast, by End User Type
12.1.6.4. Market Revenue and Forecast, by Delivery Model Type
12.2. Europe
12.2.1. Market Revenue and Forecast, by Product
12.2.2. Market Revenue and Forecast, by Application
12.2.3. Market Revenue and Forecast, by End User Type
12.2.4. Market Revenue and Forecast, by Delivery Model Type
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Product
12.2.5.2. Market Revenue and Forecast, by Application
12.2.5.3. Market Revenue and Forecast, by End User Type
12.2.5.4. Market Revenue and Forecast, by Delivery Model Type
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Product
12.2.6.2. Market Revenue and Forecast, by Application
12.2.6.3. Market Revenue and Forecast, by End User Type
12.2.6.4. Market Revenue and Forecast, by Delivery Model Type
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Product
12.2.7.2. Market Revenue and Forecast, by Application
12.2.7.3. Market Revenue and Forecast, by End User Type
12.2.7.4. Market Revenue and Forecast, by Delivery Model Type
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Product
12.2.8.2. Market Revenue and Forecast, by Application
12.2.8.3. Market Revenue and Forecast, by End User Type
12.2.8.4. Market Revenue and Forecast, by Delivery Model Type
12.3. APAC
12.3.1. Market Revenue and Forecast, by Product
12.3.2. Market Revenue and Forecast, by Application
12.3.3. Market Revenue and Forecast, by End User Type
12.3.4. Market Revenue and Forecast, by Delivery Model Type
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Product
12.3.5.2. Market Revenue and Forecast, by Application
12.3.5.3. Market Revenue and Forecast, by End User Type
12.3.5.4. Market Revenue and Forecast, by Delivery Model Type
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Product
12.3.6.2. Market Revenue and Forecast, by Application
12.3.6.3. Market Revenue and Forecast, by End User Type
12.3.6.4. Market Revenue and Forecast, by Delivery Model Type
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Product
12.3.7.2. Market Revenue and Forecast, by Application
12.3.7.3. Market Revenue and Forecast, by End User Type
12.3.7.4. Market Revenue and Forecast, by Delivery Model Type
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Product
12.3.8.2. Market Revenue and Forecast, by Application
12.3.8.3. Market Revenue and Forecast, by End User Type
12.3.8.4. Market Revenue and Forecast, by Delivery Model Type
12.4. MEA
12.4.1. Market Revenue and Forecast, by Product
12.4.2. Market Revenue and Forecast, by Application
12.4.3. Market Revenue and Forecast, by End User Type
12.4.4. Market Revenue and Forecast, by Delivery Model Type
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Product
12.4.5.2. Market Revenue and Forecast, by Application
12.4.5.3. Market Revenue and Forecast, by End User Type
12.4.5.4. Market Revenue and Forecast, by Delivery Model Type
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Product
12.4.6.2. Market Revenue and Forecast, by Application
12.4.6.3. Market Revenue and Forecast, by End User Type
12.4.6.4. Market Revenue and Forecast, by Delivery Model Type
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Product
12.4.7.2. Market Revenue and Forecast, by Application
12.4.7.3. Market Revenue and Forecast, by End User Type
12.4.7.4. Market Revenue and Forecast, by Delivery Model Type
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Product
12.4.8.2. Market Revenue and Forecast, by Application
12.4.8.3. Market Revenue and Forecast, by End User Type
12.4.8.4. Market Revenue and Forecast, by Delivery Model Type
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Product
12.5.2. Market Revenue and Forecast, by Application
12.5.3. Market Revenue and Forecast, by End User Type
12.5.4. Market Revenue and Forecast, by Delivery Model Type
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Product
12.5.5.2. Market Revenue and Forecast, by Application
12.5.5.3. Market Revenue and Forecast, by End User Type
12.5.5.4. Market Revenue and Forecast, by Delivery Model Type
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Product
12.5.6.2. Market Revenue and Forecast, by Application
12.5.6.3. Market Revenue and Forecast, by End User Type
12.5.6.4. Market Revenue and Forecast, by Delivery Model Type
13.1. Biovia
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Certara
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Compugen Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Genedata
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. In Silico Biosciences, Inc.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Leadscope Inc.
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Pharmaceutical Product Development, LLC.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Schrödinger, LLC.
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Simulations Plus, Inc.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. DassaultSystemes
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample